Pseudomonas exotoxin A-Based immunotoxins for targeted cancer therapy

Emerging Cancer Therapy: Microbial Approaches and Biotechnological Tools

Volumn , Issue , 2010, Pages 269-288

  Wolf, Philipp ^a   Elsässer Beile, Ursula ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Protein engineering increasing efficacy of PE based immunotoxins; Pseudomonas exotoxin A based immunotoxins; Pseudomonas exotoxin A based immunotoxins in targeted cancer therapy

Indexed keywords

EID: 84878692349     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470626528.ch12     Document Type: Chapter

References (87)

1. Vasil M.L. 1986 . Pseudomonas aeruginosa: biology, mechanisms of virulence, epidemiology . J. Pediatr. 108: 800-805 .
2. Green S.K. , Schroth M.N. , Cho J.J. , Kominos S.K. , and Vitanza-Jack V.B. 1974 . Agricultural plants and soil as a reservoir for Pseudomonas aeruginosa . Appl. Microbiol. 28: 987-991 .
3. Driscoll J.A. , Brody S.L. , and Kollef M.H. 2007 . The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections . Drugs. 67: 351-368 .
4. Bitter W. 2003 . Secretins of Pseudomonas aeruginosa: large holes in the outer membrane . Arch. Microbiol. 179: 307-314 .
5. Iglewski B.H. , and Kabat D. 1975 . NAD-dependent inhibition of protein synthesis by Pseudomonas aeruginosa toxin . Proc. Natl. Acad. Sci. U S A. 72: 2284-2288 .
6. Deng Q. , and Barbieri J.T. 2008 . Molecular mechanisms of the cytotoxicity of ADP-ribosylating toxins . Annu. Rev. Microbiol. 62: 271-288 .
7. Wedekind J.E. , Trame C.B. , Dorywalska M. , Koehl P. , Raschke T.M. , McKee M. , FitzGerald D. , Collier R.J. , and McKay D.B. 2001 . Refined crystallographic structure of Pseudomonas aeruginosa exotoxin A and its implications for the molecular mechanism of toxicity . J. Mol. Biol. 314: 823-837 .
8. Gordon V.M. , Klimpel K.R. , Arora N. , Henderson M.A. , and Leppla S.H. 1995 . Proteolytic activation of bacterial toxins by eukaryotic cells is performed by furin and by additional cellular proteases . Infect. Immun. 63: 82-87 .
9. Chaudhary V.K. , Jinno Y. , FitzGerald D. , and Pastan I. 1990 . Pseudomonas exotoxin contains a specific sequence at the carboxyl terminus that is required for cytotoxicity . Proc. Natl. Acad. Sci. U S A . 87: 308-312 .
10. Hessler J.L. , and Kreitman R.J. 1997 . An early step in Pseudomonas exotoxin action is removal of the terminal lysine residue, which allows binding to the KDEL receptor . Biochemistry . 36: 14577-14582 .
11. Kounnas M.Z. , Morris R.E. , Thompson M.R. , FitzGerald D.J. , Strickland D.K. , and Saelinger C.B. 1992 . The alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein binds and internalizes Pseudomonas exotoxin A . J. Biol. Chem. 267: 12420-12423 .
12. Smith D.C. , Spooner R.A. , Watson P.D. , Murray J.L. , Hodge T.W. , Amessou M. , Johannes L. , Lord J.M. , and Roberts L.M. 2006 . Internalized Pseudomonas exotoxin A can exploit multiple pathways to reach the endoplasmic reticulum . Traffic. 7: 379-393 .
13. Wolf P. , and Elsasser-Beile U. 2009 . Pseudomonas exotoxin A: from virulence factor to anti-cancer agent . Int. J. Med. Microbiol. 299: 161-176 .
14. Ogata M. , Fryling C.M. , Pastan I. , and FitzGerald D.J. 1992 . Cell-mediated cleavage of Pseudomonas exotoxin between Arg279 and Gly280 generates the enzymatically active fragment which translocates to the cytosol . J. Biol. Chem. 267: 25396-25401 .
15. Ogata M. , Chaudhary V.K. , Pastan I. , and FitzGerald D.J. 1990 . Processing of Pseudomonas exotoxin by a cellular protease results in the generation of a 37,000-Da toxin fragment that is translocated to the cytosol . J. Biol. Chem. 265: 20678-20685 .
16. McKee M.L. , and FitzGerald D.J. 1999 . Reduction of furin-nicked Pseudomonas exotoxin A: an unfolding story . Biochemistry . 38: 16507-16513 .
17. Lombardi D. , Soldati T. , Riederer M.A. , Goda Y. , Zerial M. , and Pfeffer S.R. 1993 . Rab9 functions in transport between late endosomes and the trans Golgi network . EMBO J. 12: 677-682 .
18. Jackson M.E. , Simpson J.C. , Girod A. , Pepperkok R. , Roberts L.M. , and Lord J.M. 1999 . The KDEL retrieval system is exploited by Pseudomonas exotoxin A, but not by Shiga-like toxin-1, during retrograde transport from the Golgi complex to the endoplasmic reticulum . J. Cell Sci. 112: 467-475 .
19. Koopmann J.O. , Albring J. , Hüter E. , Bulbuc N. , Spee P. , Neefjes J. , Hämmerling G.J. , and Momburg F. 2000 . Export of antigenic peptides from the endoplasmic reticulum intersects with retrograde protein translocation through the Sec61p channel . Immunity . 13: 117-127 .
20. Iglewski B.H. , Liu P.V. , and Kabat D. 1977 . Mechanism of action of Pseudomonas aeruginosa exotoxin A in adenosine diphosphate-ribosylation of mammalian elongation factor 2 in vitro and in vivo . Infect. Immun. 15: 138-144 .
21. Jørgensen R. , Merrill A.R. , Yates S.P. , Marquez V.E. , Schwan A.L. , Boesen T. , and Andersen G.R. 2005 . Exotoxin A-eEF2 complex structure indicates ADP ribosylation by ribosome mimicry . Nature . 436: 979-984 .
22. Ortiz P.A. , and Kinzy T.G. 2005 . Dominant-negative mutant phenotypes and the regulation of translation elongation factor 2 levels in yeast . Nucleic Acids Res. 33: 5740-5748 .
23. Chang J.H. , and Kwon H.Y. 2007 . Expression of 14-3-3delta, cdc2 and cyclin B proteins related to exotoxin A-induced apoptosis in HeLa S3 cells . Int. Immunopharmacol. 7: 1185-1191 .
24. Jenkins C.E. , Swiatoniowski A. , Issekutz A.C. , Lin T.J. 2004 . Pseudomonas aeruginosa exotoxin A induces human mast cell apoptosis by a caspase-8 and-3-dependent mechanism . J. Biol. Chem. 279: 37201-37207 .
25. Frankel A.E. , Kreitman R.J. , and Sausville E.A. 2000 . Targeted toxins . Clin. Cancer Res. 6: 326-334 .
26. Michl P. , and Gress T.M. 2004 . Bacteria and bacterial toxins as therapeutic agents for solid tumors . Curr. Cancer Drug Targets. 4: 689-702 .
27. Pastan I. , Hassan R. , FitzGerald D.J. , and Kreitman R.J. 2007 . Immunotoxin treatment of cancer . Annu. Rev. Med. 58: 221-237 .
28. Kreitman R.J. , Wilson W.H. , Bergeron K. , Raggio M. , Stetler-Stevenson M. , FitzGerald D.J. , and Pastan I. 2001 . Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia . N. Engl. J. Med. 345: 241-247 .
29. Kreitman R.J. , Squires D.R. , Stetler-Stevenson M. , Noel P. , FitzGerald D.J. , Wilson W.H. , and Pastan I. 2005 . Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies . J. Clin. Oncol. 23: 6719-6729 .
30. Kreitman R.J. , Squires D.R. , Stetler-Stevenson M. , Noel P. , FitzGerald D.J. , Wilson W.H. , and Pastan I. 2000 . Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies . J. Clin. Oncol. 18: 1622-1636 .
31. Kreitman R.J. , Wilson W.H. , Robbins D. , Margulies I. , Stetler-Stevenson M. , Waldmann T.A. , and Pastan I. 1999 . Responses in refractory hairy cell leukemia to a recombinant immunotoxin . Blood. 94: 3340-3348 .
32. Biggers K. , and Scheinfeld N. 2008 . VB4-845, a conjugated recombinant antibody and immunotoxin for head and neck cancer and bladder cancer . Curr. Opin. Mol. Ther. 10: 176-186 .
33. Rand R.W. , Kreitman R.J. , Patronas N. , Varricchio F. , Pastan I. , and Puri R.K. 2000 . Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma . Clin. Cancer Res. 6: 2157-2165 .
34. Weber F. , Asher A. , Bucholz R. , et al. 2003 . Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma . J. Neurooncol. 64: 125-137 .
35. Garland L. , Gitlitz B. , Ebbinghaus S. , Pan H. , de Haan H. , Puri R.K. , Von Hoff D. , and Figlin R. 2005 . Phase I trial of intravenous IL-4 pseudomonas exotoxin protein (NBI-3001) in patients with advanced solid tumors that express the IL-4 receptor . J. Immunother. 28: 376-381 .
36. Pai , L.H. , Bookman M.A. , Ozols R.F. , Young R.C. , Smith J.W. , Longo D.L. , Gould B. , Frankel A. , McClay E.F. , Howell S. , Reed E. , Willingham M.C. , Fitzgerald D.J. , and Paston I. 1991 . Clinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer . J. Clin. Oncol. 9: 2095-2103 .
37. Pai L.H. , Wittes R. , Setser A. , Willingham M.C. , and Pastan I. 1996 . Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin . Nat. Med. 2: 350-353 .
38. Posey J.A. , Khazaeli M.B. , Bookman M.A. , et al. 2002 . A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors . Clin. Cancer Res. 8: 3092-3099 .
39. Pai-Scherf L.H. , Villa J. , Pearson D. , Watson T. , Liu E. , Willingham M.C. , and Pastan I. 1999 . Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor . Clin. Cancer Res. 5: 2311-2315 .
40. Azemar M. , Djahansouzi S. , Jäger E. , Solbach C. , Schmidt M. , Maurer A.B. , Mross K. , Unger C. , von Minckwitz G. , Dall P. , Groner B. , Wels W.S. 2003 . Regression of cutaneous tumor lesions in patients intratumorally injected with a recombinant single-chain antibody-toxin targeted to ErbB2/HER2 . Breast Cancer Res. Treat. 82: 155-164 .
41. von Minckwitz G. , Harder S. , Hövelmann S. , Jäger E. , Al-Batran S.E. , Loibl S. , Atmaca A. , Cimpoiasu C. , Neumann A. , Abera A. , Knuth A. , Kaufmann M. , Jäger D. , Maurer A.B. , and Wels W.S. 2005 . Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas . Breast Cancer Res. 7: R617-R626 .
42. Hassan R. , Bullock S. , Premkumar A. , Kreitman R.J. , Kindler H. , Willingham M.C. , and Pastan I. 2007 . Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers . Clin. Cancer Res. 13: 5144-5149 .
43. Alderson R.F. , Kreitman R.J. , Chen T. , Yeung P. , Herbst R. , Fox J.A. , and Pastan I. 2009 . CAT-8015: a second-generation pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignancies . Clin. Cancer Res. 15: 832-839 .
44. Weldon J.E. , Xiang L. , Chertov O. , Margulies I. , Kreitman R.J. , FitzGerald D.J. , and Pastan I. 2009 . A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity . Blood. 113: 3792-3800 .
45. Schumann J. , Angermuller S. , Bang R. , Lohoff M. , and Tiegs G. 1998 . Acute hepatotoxicity of Pseudomonas aeruginosa exotoxin A in mice depends on T cells and TNF . J. Immunol. 161: 5745-5754 .
46. Vitetta E.S. 2000. Immunotoxins and vascular leak syndrome . Cancer J. 6 ( Suppl. 3): S218-S224 .
47. Baluna R. , Rizo J. , Gordon B.E. , Ghetie V. , Vitetta E.S. 1999 . Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome . Proc. Natl. Acad. Sci. U S A. 96: 3957-3962 .
48. Baluna R. , and Vitetta E.S. 1997 . Vascular leak syndrome: a side effect of immunotherapy . Immunopharmacology. 37: 117-132 .
49. Almagro J.C. , and Fransson J. 2008 . Humanization of antibodies . Front. Biosci. 13: 1619-1633 .
50. Onda M. , Beers R. , Xiang L. , Nagata S. , Wang Q.C. , and Pastan I. 2008 . An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes . Proc. Natl. Acad. Sci. U S A . 105: 11311-11316 .
51. Tsutsumi Y. , Onda M. , Nagata S. , Lee B. , Kreitman R.J. , and Pastan I. 2000 . Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity . Proc. Natl. Acad. Sci. U S A. 97: 8548-8553 .
52. Chen H. , Gao J. , Lu Y. , Kou G. , Zhang H. , Fan L. , Sun Z. , Guo Y. , and Zhong Y. 2008 . Preparation and characterization of PE38KDEL-loaded anti-HER2 nanoparticles for targeted cancer therapy . J. Control Release. 128: 209-216 .
53. Willingham M.C. , FitzGerald D.J. , and Pastan I. 1987 . Pseudomonas exotoxin coupled to a monoclonal antibody against ovarian cancer inhibits the growth of human ovarian cancer cells in a mouse model . Proc. Natl. Acad. Sci. U S A . 84: 2474-2478 .
54. Pastan I. 1997 . Targeted therapy of cancer with recombinant immunotoxins . Biochim. Biophys. Acta. 1333: C1-C6 .
55. Hjortland G.O. , Garman-Vik S.S. , Juell S. , Olsen O.E. , Hirschberg H. , Fodstad O. , and Engebraaten O. 2004 . Immunotoxin treatment targeted to the high-molecular-weight melanoma-associated antigen prolonging the survival of immunodeficient rats with invasive intracranial human glioblastoma multiforme . J. Neurosurg. 100: 320-327 .
56. Schwemmlein M. , Stieglmaier J. , Kellner C. , Peipp M. , Saul D. , Oduncu F. , Emmerich B. , Stockmeyer B. , Lang P. , Beck J.D. , and Fey G.H. 2007 . A CD19-specific single-chain immunotoxin mediates potent apoptosis of B-lineage leukemic cells . Leukemia. 21: 1405-1412 .
57. Kreitman R.J. , Bailon P. , Chaudhary V.K. , FitzGerald D.J. , and Pastan I. 1994 . Recombinant immunotoxins containing anti-Tac(Fv) and derivatives of Pseudomonas exotoxin produce complete regression in mice of an interleukin-2 receptor-expressing human carcinoma . Blood . 83: 426-434 .
58. Barth S. , Huhn M. , Wels W. , Diehl V. , and Engert A. 1998 . Construction and in vitro evaluation of RFT5(scFv)-ETA ' , a new recombinant single-chain immunotoxin with specific cytotoxicity toward CD25+ Hodgkin-derived cell lines . Int. J. Mol. Med. 1: 249-256 .
59. Kreitman R.J. , Margulies I. , Stetler-Stevenson M. , Wang Q.C. , FitzGerald D.J. , and Pastan I. 2000 . Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias . Clin. Cancer Res. 6: 1476-1487 .
60. Francisco J.A. , Schreiber G.J. , Comereski C.R. , Mezza L.E. , Warner G.L. , Davidson T.J. , Ledbetter J.A. , and Siegall C.B. 1997 . In vivo efficacy and toxicity of a single-chain immunotoxin targeted to CD40 . Blood . 89: 4493-4500 .
61. Benhar I. , Reiter Y. , Pai L.H. , and Pastan I. 1995 . Administration of disulfide-stabilized Fv-immunotoxins B1(dsFv)-PE38 and B3(dsFv)-PE38 by continuous infusion increases their efficacy in curing large tumor xenografts in nude mice . | Int. J. Cancer . 62: 351-355 .
62. Friedman P.N. , McAndrew S.J. , Gawlak S.L. , Chace D. , Trail P.A. , Brown J.P. , and Siegall C.B. 1993 . BR96 sFv-PE40, a potent single-chain immunotoxin that selectively kills carcinoma cells . Cancer Res. 53: 334-339 .
63. Leland P. , Taguchi J. , Husain S.R. , Kreitman R.J. , Pastan I. , and Puri R.K. 2000 . Human breast carcinoma cells express type II IL-4 receptors and are sensitive to antitumor activity of a chimeric IL-4-Pseudomonas exotoxin fusion protein in vitro and in vivo . Mol. Med. 6: 165-178 .
64. Kawakami K. , Leland P. , and Puri R.K. 2000 . Structure, function, and targeting of interleukin 4 receptors on human head and neck cancer cells . Cancer Res. 60: 2981-2987 .
65. Kawakami K. , Kawakami M. , Husain S.R. , and Puri R.K. 2002 . Targeting interleukin-4 receptors for effective pancreatic cancer therapy . Cancer Res. 62: 3575-3580 .
66. Ishige K. , Shoda J. , Kawamoto T. , Matsuda S. , Ueda T. , Hyodo I. , Ohkohchi N. , Puri R.K. , and Kawakami K. 2008 . Potent in vitro and in vivo antitumor activity of interleukin-4-conjugated Pseudomonas exotoxin against human biliary tract carcinoma . Int. J. Cancer . 123: 2915-2922 .
67. Kawakami K. , Kawakami M. , Joshi B.H. , and Puri R.K. 2001 . Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer . Cancer Res. 61: 6194-6200 .
68. Kioi M. , Seetharam S. , and Puri R.K. 2008 . Targeting IL-13Ralpha2-positive cancer with a novel recombinant immunotoxin composed of a single-chain antibody and mutated Pseudomonas exotoxin . Mol. Cancer Ther. 7: 1579-1587 .
69. Wels W. , Harwerth I.M. , Mueller M. , Groner B. , Hynes N.E. 1992 . Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor . Cancer Res. 52: 6310-6317 .
70. Wang L. , Liu B. , Schmidt M. , Lu Y. , Wels W. , and Fan Z. 2001 . Antitumor effect of an HER2-specific antibody-toxin fusion protein on human prostate cancer cells . Prostate . 47: 21-28 .
71. Skrepnik N. , Araya J.C. , Qian Z. , Xu H. , Hamide J. , Mera R. , and Hunt J.D. 1996 . Effects of anti-erbB-2 (HER-2/neu) recombinant oncotoxin AR209 on human non-small cell lung carcinoma grown orthotopically in athymic nude mice . Clin. Cancer Res. 2: 1851-1857 .
72. Skrepnik N. , Zieske A.W. , Bravo J.C. , Gillespie A.T. , and Hunt J.D. 1999 . Recombinant oncotoxin AR209 (anti-P185erbB-2) diminishes human prostate carcinoma xenografts . J. Urol. 161: 984-989 .
73. Reiter Y. , and Pastan I. 1996 . Antibody engineering of recombinant Fv immunotoxins for improved targeting of cancer: disulfide-stabilized Fv immunotoxins . Clin. Cancer Res. 2: 245-252 .
74. Sampson J.H. , Akabani G. , Archer G.E. , Bigner D.D. , Berger M.S. , Friedman A.H. , Friedman H.S. , Herndon J.E. II , Kunwar S. , Marcus S. , McLendon R.E. , Paolino A. , Penne K. , Provenzale J. , Quinn J. , Reardon D.A. , Rich J. , Stenzel T. , Tourt-Uhlig S. , Wikstrand C. , Wong T. , Williams R. , Yuan F. , Zalutsky M.R. , and Pastan I. 2003 . Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors . J. Neurooncol. 65: 27-35 .
75. Pai L.H. , Gallo M.G. , FitzGerald D.J. , Pastan I. 1991 . Antitumor activity of a transforming growth factor alpha-Pseudomonas exotoxin fusion protein (TGF-alpha-PE40) . Cancer Res. 51: 2808-2812 .
76. Kunwar S. , Pai L.H. , and Pastan I. 1993 . Cytotoxicity and antitumor effects of growth factor-toxin fusion proteins on human glioblastoma multiforme cells . J. Neurosurg. 79: 569-576 .
77. Wolf P. , Gierschner D. , Buhler P. , Wetterauer U. , Elsasser-Beile U. 2006 . A recombinant PSMA-specific single-chain immunotoxin has potent and selective toxicity against prostate cancer cells . Cancer Immunol. Immunother. 55: 1367-1373 .
78. Wolf P. , Alt K. , Bühler P. , Katzenwadel A. , Wetterauer U. , Tacke M. , and Elsässer-Beile U. 2008 . Anti-PSMA immunotoxin as novel treatment for prostate cancer? High and specific antitumor activity on human prostate xenograft tumors in SCID mice . Prostate . 68: 129-138 .
79. Hassan R. , Lerner M.R. , Benbrook D. , Lightfoot S.A. , Brackett D.J. , Wang Q.C. , and Pastan I. 2002 . Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro . Clin. Cancer Res. 8: 3520-3526 .
80. Onda M. , Wang Q.C. , Guo H.F. , Cheung N.K. , and Pastan I. 2004 . In vitro and in vivo cytotoxic activities of recombinant immunotoxin 8H9(Fv)-PE38 against breast cancer, osteosarcoma, and neuroblastoma . Cancer Res. 64: 1419-1424 .
81. Di Paolo C. , Willuda J. , Kubetzko S. , Lauffer I. , Tschudi D. , Waibel R. , Plückthun A. , Stahel R.A. , and Zangemeister-Wittke U. 2003 . A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity . Clin. Cancer Res. 9: 2837-2848 .
82. Shinohara H. , Fan D. , Ozawa S. , Yano S. , Van Arsdell M. , Viner J.L. , Beers R. , Pastan I. , and Fidler I.J. 2000 . Site-specific expression of transferrin receptor by human colon cancer cells directly correlates with eradication by antitransferrin recombinant immunotoxin . Int. J. Oncol. 17: 643-651 .
83. Baatar D. , Olkhanud P. , Newton D. , Sumitomo K. , Biragyn A. 2007 . CCR4-expressing T cell tumors can be specifically controlled via delivery of toxins to chemokine receptors . J. Immunol. 179: 1996-2004 .
84. Klechevsky E. , Gallegos M. , Denkberg G. , Palucka K. , Banchereau J. , Cohen C. , and Reiter Y. 2008 . Antitumor activity of immunotoxins with T-cell receptor-like specificity against human melanoma xenografts . Cancer Res. 68: 6360-6367 .
85. Kunwar S. , Prados M.D. , Chang S.M. , Berger M.S. , Lang F.F. , Piepmeier J.M. , Sampson J.H. , Ram Z. , Gutin P.H. , Gibbons R.D. , Aldape K.D. , Croteau D.J. , Sherman J.W. , and Puri R.K. 2007 . Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group . J. Clin. Oncol. 25: 837-844 .
86. Sampson J.H. , Akabani G. , Archer G.E. , Berger M.S. , Coleman R.E. , Friedman A.H. , Friedman H.S. , Greer K. , Herndon J.E. II , Kunwar S. , McLendon R.E. , Paolino A. , Petry N.A. , Provenzale J.M. , Reardon D.A. , Wong T.Z. , Zalutsky M.R. , Pastan I. , and Bigner D.D. 2008 . Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors . Neuro. Oncol. 10: 320-329 .
87. Goldberg M.R. , Heimbrook D.C. , Russo P. , Sarosdy M.F. , Greenberg R.E. , Giantonio B.J. , Linehan W.M. , Walther M. , Fisher H.A.G. , Messing E. , Crawford E.D. , Ollif A.I. and Pastan I.H. 1995 . Phase I clinical study of the recombinant oncotoxin TP40 in superficial bladder cancer . Clin. Cancer Res. 1: 57-61 .